The University of Chicago Header Logo

Connection

Koen Van Besien to Remission Induction

This is a "connection" page, showing publications Koen Van Besien has written about Remission Induction.
Connection Strength

1.106
  1. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020 10 27; 4(20):5146-5156.
    View in: PubMed
    Score: 0.156
  2. A renaissance for autologous transplantation in follicular lymphoma? Leuk Lymphoma. 2019 01; 60(1):3-5.
    View in: PubMed
    Score: 0.133
  3. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45.
    View in: PubMed
    Score: 0.083
  4. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012 Mar; 53(3):371-80.
    View in: PubMed
    Score: 0.083
  5. Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects? Leuk Lymphoma. 2008 Sep; 49(9):1651-2.
    View in: PubMed
    Score: 0.067
  6. Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leuk Lymphoma. 2007 Apr; 48(4):816-8.
    View in: PubMed
    Score: 0.061
  7. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.054
  8. Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant. Curr Treat Options Oncol. 2005 Jul; 6(4):279-87.
    View in: PubMed
    Score: 0.054
  9. Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfus Apher Sci. 2005 Feb; 32(1):45-53.
    View in: PubMed
    Score: 0.052
  10. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15; 102(10):3521-9.
    View in: PubMed
    Score: 0.047
  11. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404.
    View in: PubMed
    Score: 0.040
  12. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. Leuk Lymphoma. 2018 01; 59(1):256-258.
    View in: PubMed
    Score: 0.031
  13. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol. 1997 May; 65(2):366-9.
    View in: PubMed
    Score: 0.031
  14. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42.
    View in: PubMed
    Score: 0.030
  15. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102.
    View in: PubMed
    Score: 0.027
  16. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70.
    View in: PubMed
    Score: 0.024
  17. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.021
  18. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
    View in: PubMed
    Score: 0.019
  19. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64.
    View in: PubMed
    Score: 0.018
  20. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.016
  21. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb; 27(4):387-96.
    View in: PubMed
    Score: 0.010
  22. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15; 19(2):406-13.
    View in: PubMed
    Score: 0.010
  23. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8.
    View in: PubMed
    Score: 0.010
  24. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999 Feb; 17(2):534-45.
    View in: PubMed
    Score: 0.009
  25. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.
    View in: PubMed
    Score: 0.008
  26. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
    View in: PubMed
    Score: 0.008
  27. Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol. 1997; 18(6):453-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.